Bladder cancer is the tenth most common cancer type worldwide. Urothelial carcinoma is the
most common type of bladder cancer and accounts for 90% of bladder cancer cases in the …

Purpose Cisplatin-based combination chemotherapy is considered standard first-line
treatment for patients with metastatic urothelial carcinoma. However, a large proportion of …

PURPOSE To assess the safety/tolerability and antitumor activity of enfortumab vedotin (EV),
a novel investigational antibody-drug conjugate that delivers the microtubule-disrupting …

PURPOSE: Gemcitabine plus cisplatin (GC) and methotrexate, vinblastine, doxorubicin, and
cisplatin (MVAC) were compared in patients with locally advanced or metastatic transitional …

Purpose To compare long-term survival in patients with locally advanced or metastatic
transitional cell carcinoma (TCC) of the urothelium treated with gemcitabine/cisplatin (GC) or …

PURPOSE: The variation in reported survival of patients with metastatic transitional-cell
carcinoma (TCC) treated with systemic chemotherapy may be a consequence of …

Background Few treatments with a distinct mechanism of action are available for patients
with platinum-refractory advanced or metastatic urothelial carcinoma. We assessed the …

Purpose: Resistance to cisplatin-based chemotherapy is a major obstacle to bladder cancer
treatment. We aimed to identify microRNAs (miRNA) that are dysregulated in cisplatin …

PURPOSE: This randomized trial evaluated antitumor activity of and survival asociated with
high–dose-intensity chemotherapy with methotrexate, vinblastine, doxorubicin, and cisplatin …

Bladder cancer is the fourth most common cancer and ranks eighth as a cause of death from
cancer among men in the United States. Although guidelines assist in treatment, the art of …